Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q1 2021 Earnings Presentation
14 slides from Bionano Genomics's earnings presentation, May 13, 2021
Slide 1: Q1 2021 Webcast & Call
May 13, 2021 Q1 2021 Webcast & Call
Slide 2: Legal Disclaimer
2 Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estim
Slide 3: 2021: Off to a Solid Start for Bionano
3 2021: Off to a Solid Start for Bionano Q1 New applications in prenatal testing, cancer research & development 11 16 Increased speed of cloud computing solution by 30%, reducing cost to end user by 50% Talks and posters Saphyr Shipped 107 total installed base Advancing Go to Market – Bionano Data C
Slide 4: Key Steps to Widespread Global Adoption of Saphyr
4 Development multiple assays across a wide range of applications in human clinical research Key Steps to Widespread Global Adoption of Saphyr Publication of multiple large studies showing concordance with the existing methods A clear path for users to seek payment for OGM services they offer Goal:
Slide 5: Bionano Data Contributes to Advances in Research
5 Bionano Data Contributes to Advances in Research ALS Resolved mosaic repeat expansions Alzheimer’s Disease Identified deletions in CR1 Leukemia In 12 patients, found dozens of novel genes with recurring structural variants Hepatocellular Carcinoma Identified Hep B Virus insertion that caused tumor
Slide 6: Advanced and Optimized the Performance of the Saphyr System
6 Advanced and Optimized the Performance of the Saphyr System for Adoption in Labs to Support Development of Clinical Assays and LDTs Launched an LDT for whole genome analysis with OGM for constitutional genetic disease • Developing LDTs for prenatal testing and solid tumor analysis Anticipated ac
Slide 7: Lineagen Adds Revenue & Accelerates Clinical Adoption of Saphyr
7 Lineagen Adds Revenue & Accelerates Clinical Adoption of Saphyr ESSENTIAL COMPONENTS FOR BUILDING REIMBURSED DX MENU ON SAPHYR Trained billing specialists lay groundwork for reimbursement of Saphyr LDTs COMBINING PRODUCT- AND SERVICE-BASED BUSINESSES Proprietary database from Toronto Sick Kids Hos
Slide 8: Clinical Affairs Summary
Clinical Affairs Summary Dr. Alka Chaubey CMO achaubey@bionanogenomics.com
Slide 9: Four Large Clinical Studies Getting Underway
9 Four Large Clinical Studies Getting Underway to Support Penetration of our Target Markets & Economic Benefits of Using OGM Constitutional - Prenatal - Constitutional - Pediatric - Oncology - Heme Malignancies - Oncology - Solid Tumor - Amnio & CVS Illustrate HOW OGM can help with NIPT + and no-cal
Slide 10: Financial Overview
Financial Overview Chris Stewart CFO cstewart@bionanogenomics.com
Slide 11: Q1 2021 – Financial Results and Key Highlights
11 Q1 2021 – Financial Results and Key Highlights • Total revenue was $3.2M, up 179% from Q1 2020 • Year on year, revenue was up in all geographies and across both product and service revenue • Raised $337M from two underwritten public offerings, utilization ATM facility and exercise of outstanding
Slide 12: Summary
Summary R. Erik Holmlin CEO eholmlin@bionanogenomics.com
Slide 13: Key Anticipated Milestones Expected to Drive Value for BNGO
13 • Commercial release of prenatal assays for Saphyr and expansion of Saphyr’s menu of pediatric assays Key Anticipated Milestones Expected to Drive Value for BNGO 3Q • Accreditation of Saphyr based LDTs for ALL & FSHD in certain EU markets 2Q 4Q • Interim publication of results from pediatric clin
Slide 14: Questions & Answers
Questions & Answers Contact: R. Erik Holmlin CEO eholmlin@bionanogenomics.com Chris Stewart CFO cstewart@bionanogenomics.com